SLANG Worldwide Past Earnings Performance
Past criteria checks 0/6
SLANG Worldwide has been growing earnings at an average annual rate of 30%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 11.7% per year.
Key information
30.0%
Earnings growth rate
50.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 11.7% |
| Return on equity | n/a |
| Net Margin | -102.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How SLANG Worldwide makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 29 | -30 | 21 | 0 |
| 31 Mar 24 | 32 | -23 | 22 | 0 |
| 31 Dec 23 | 35 | -19 | 22 | 0 |
| 30 Sep 23 | 40 | -27 | 23 | 0 |
| 30 Jun 23 | 39 | -29 | 24 | 0 |
| 31 Mar 23 | 40 | -28 | 25 | 0 |
| 31 Dec 22 | 38 | -29 | 26 | 0 |
| 30 Sep 22 | 35 | -47 | 28 | 0 |
| 30 Jun 22 | 36 | -48 | 30 | 0 |
| 31 Mar 22 | 37 | -48 | 31 | 0 |
| 31 Dec 21 | 37 | -51 | 33 | 0 |
| 30 Sep 21 | 36 | -52 | 29 | 0 |
| 30 Jun 21 | 34 | -52 | 25 | 0 |
| 31 Mar 21 | 26 | -45 | 27 | 0 |
| 31 Dec 20 | 22 | -14 | 27 | 0 |
| 30 Sep 20 | 21 | -187 | 49 | 0 |
| 30 Jun 20 | 23 | -178 | 53 | 0 |
| 31 Mar 20 | 27 | -162 | 52 | 0 |
| 31 Dec 19 | 26 | -200 | 51 | 0 |
| 30 Sep 19 | 22 | 9 | 28 | 0 |
| 30 Jun 19 | 15 | -10 | 31 | 0 |
| 31 Mar 19 | 8 | -42 | 26 | 0 |
| 31 Dec 18 | 5 | -28 | 20 | 0 |
| 30 Sep 18 | 3 | -31 | 15 | 0 |
| 31 Dec 17 | 0 | -1 | 0 | 0 |
Quality Earnings: 84SA is currently unprofitable.
Growing Profit Margin: 84SA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 84SA is unprofitable, but has reduced losses over the past 5 years at a rate of 30% per year.
Accelerating Growth: Unable to compare 84SA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 84SA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 84SA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.